(Source: Xencor Inc) MONROVIA, Calif., Feb. 22, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release fourth quarter and full year 2016 financial results after the market closes on Tuesday, February 28, 2017. Xencor...
↧